You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗	D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults	Completed	Gilead Sciences	Phase 2	2012-04-01	This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Condition Name

Chart
Table

Condition Name for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV	9
HIV-1 Infection	9
HIV Infections	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV Infections	16
Acquired Immunodeficiency Syndrome	9
Immunologic Deficiency Syndromes	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Trials by Country

Map
Table

Trials by Country for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
United States	293
Canada	39
United Kingdom	17
France	17
Spain	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
California	18
Florida	17
Georgia	15
Texas	15
Missouri	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	19
Phase 2	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Completed	22
Not yet recruiting	7
Recruiting	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Sponsor Name

Chart
Table

Sponsor Name for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Gilead Sciences	25
National Institute of Allergy and Infectious Diseases (NIAID)	3
University of California, San Diego	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Other	41
Industry	29
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.